Murine models define the role of TGF-β as a master regulator of immune cell function

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 81-87

  Letterio, John J ^a  

^a Laboratory of Human Carcinogenesis   (United States)

Author keywords

Immune cell; Mice; Smad; Transforming growth factor (TGF )

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; DNA BINDING PROTEIN; PROTEIN SMAD3; SMAD PROTEIN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; GENE MUTATION; GENETIC ENGINEERING; GENETICS; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGY; LYMPHOID CELL; METABOLISM; MOUSE; MOUSE MUTANT; NONHUMAN; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; DNA-BINDING PROTEINS; IMMUNE SYSTEM; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0034065392     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00031-3     Document Type: Review

References (53)

1. Frolik C.A., Dart L.L., Meyers C.A., et al. Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc. Natl. Acad. Sci. USA. 80:1983;3676-3680.
2. Assoian R.K., Komoriya A., Meyers C.A., et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258:1983;7155-7160.
3. Sporn M.B., Roberts A.B. Autocrine secretion - 10 years later. Ann. Intern. Med. 117:(5):1992;408-414.
4. Kehrl J.H., Wakefield L.M., Roberts A.B., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1986;1037-1050.
5. Kehrl J.H., Roberts A.B., Wakefield L.M., et al. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137:1986;3855-3860.
6. Kehrl J.H., Taylor A.S., Delsing G.A., et al. Further studies of the role of transforming growth factor-beta in human B cell function. J. Immunol. 143:1989;1868-1874.
7. Kehrl J.H., Taylor A., Kim S.J., et al. Transforming growth factor-beta is a potent negative regulator of human lymphocytes. Ann. NY Acad. Sci. 628:1991;345-353.
8. Coffman R.L., Lebman D.A., Shrader B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J. Exp. Med. 170:1989;1039-1044.
9. Keller J.R., Mantel C., Sing G.K., et al. Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J. Exp. Med. 168:1988;737-750.
10. Keller J.R., Mcniece I.K., Sill K.T., et al. Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. Blood. 75:1990;596-602.
11. Keller J.R., Jacobsen S.E., Sill K.T., et al. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc. Natl. Acad. Sci. USA. 88:1991;7190-7194.
12. Chenu C., Pfeilschifter J., Mundy G.R., et al. Transforming growth factor beta inhibits formation of osteoclast- like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA. 85:1988;5683-5687.
13. Mitjavila M.T., Vinci G., Villeval J.L., et al. Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: its relationship to type beta transforming growth factor (TGF-beta). J. Cell Physiol. 134:1988;93-100.
14. Miller K.L., Carlino J.A., Ogawa Y., et al. Alterations in erythropoiesis in TGF-beta 1-treated mice. Exp. Hematol. 20:1992;951-956.
15. Bottinger E.P., Letterio J.J., Roberts A.B. Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int. 51:1997;1355-1360.
16. Doetschman T. Interpretation of phenotype in genetically engineered mice [see comments]. Lab. Anim. Sci. 49:1999;137-143.
17. Letterio J.J., Bottinger E.P. TGF-beta knockout and dominant-negative receptor transgenic mice. Miner. Electrolyte Metab. 24:1998;161-167.
18. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 397:1999;710-713.
19. Nakashima K., Yanagisawa M., Arakawa H., et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300 [see comments]. Science. 284:1999;479-482.
20. Bright J.J., Sriram S. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J. Immunol. 161:1998;1772-1777.
21. Kulkarni A.B., Huh C.G., Becker D., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA. 90:1993;770-774.
22. Shull M.M., Ormsby I., Kier A.B., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 359:1992;693-699.
23. Yang X., Letterio J.J., Lechleider R.J., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta [In Process Citation]. EMBO J. 18:1999;1280-1291.
24. Datto M.B., Frederick J.P., Pan L., et al. Targeted Disruption of Smad3 Reveals an Essential Role in Transforming Growth Factor beta-Mediated Signal Transduction. Mol. Cell Biol. 19:1999;2495-2504.
25. Stoeck M., Miescher S., MacDonald H.R., et al. Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line. J. Cell Physiol. 141:1989;65-73.
26. Geiser A.G., Letterio J.J., Kulkarni A.B., et al. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc. Natl. Acad. Sci. USA. 90:1993;9944-9948.
27. Christ M., McCartney-Francis N.L., Kulkarni A.B., et al. Immune dysregulation in TGF-beta 1-deficient mice. J. Immunol. 153:1994;1936-1946.
28. Kulkarni A.B., Ward J.M., Yaswen L., et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146:1995;264-275.
29. Letterio J.J., Geiser A.G., Kulkarni A.B., et al. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 98:1996;2109-2119.
30. Takahama Y., Letterio J.J., Suzuki H., et al. Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor beta. J. Exp. Med. 179:1994;1495-1506.
31. Diebold R.J., Eis M.J., Yin M., et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc. Natl. Acad. Sci. USA. 92:1995;12,215-12,219.
32. Borkowski T.A., Letterio J.J., Farr A.G., et al. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184:1996;2417-2422.
33. Borkowski T.A., Letterio J.J., Mackall C.L., et al. A role for TGFbeta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFbeta1 null mice. J. Clin. Invest. 100:1997;575-581.
34. Geissmann F., Prost C., Monnet J.P., et al. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J. Exp. Med. 187:1998;961-966.
35. Riedl E., Strobl H., Majdic O., et al. TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 158:1997;1591-1597.
36. Strobl H., Riedl E., Scheinecker C., et al. TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J. Immunol. 157:1996;1499-1507.
37. Grady W.M., Myeroff L.L., Swinler S.E., et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 59:1999;320-324.
38. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
39. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
40. Howe J.R., Roth S., Ringold J.C., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:1998;1086-1088.
41. Takaku K., Oshima M., Miyoshi H., et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 92:1998;645-656.
42. Zhu Y., Richardson J.A., Parada L.F., et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.
43. Engle S.J., Hoying J.B., Boivin G.P., et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59:1999;3379-3386.
44. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 67:1998;753-791.
45. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
46. Chang H., Huylebroeck D., Verschueren K., et al. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development. 126:1999;1631-1642.
47. Yang X., Castilla L.H., Xu X., et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development. 126:1999;1571-1580.
48. Weinstein M., Yang X., Li C., et al. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc. Natl. Acad. Sci. USA. 95:1998;9378-9383.
49. Bruno E., Horrigan S.K., Van Den Berg D., et al. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood. 91:1998;1917-1923.
50. van Ginkel F.W., Wahl S.M., Kearney J.F., et al. Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. J. Immunol. 163:1999;1951-1957.
51. Ascroft G.S., Yang X., Glick A., Weinstein M., Letterio J.J., Mizel D.E., Anzano M., Greenwell-Wild T., Wahl S.M., Deng C., Roberts A.B. Mice lacking SMAD3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol. 1:1999;260-266.
52. Dang H., Geiser A.G., Letterio J.J., et al. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J. Immunol. 155:1995;3205-3212.
53. Yaswen L., Kulkarni A.B., Fredrickson T., et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 87:1996;1439-1445.